Early Diagnosis and Preventive Therapy in Parkinson’s Disease

Front Matter....Pages I-XIV
The premorbid personality of patients with Parkinson’s disease....Pages 1-7
Parkinson’s disease: development of dementia in aging....Pages 9-17
Psychometric assessment of early signs of dementia in special consideration of Parkinson’s and Alzheimer’s disease—an update....Pages 19-32
Sensory and musculo-skeletal dysfunction in Parkinson’s disease—premonitory and permanent....Pages 33-39
Autonomic nervous system screening in patients with early Parkinson’s disease....Pages 41-48
Clinical and biochemical characteristics of early depression in Parkinson’s disease....Pages 49-54
Psychomotor investigations in depressed patients by comparison with Parkinson patients....Pages 55-63
Quantitative analysis of voluntary and involuntary motor phenomena in Parkinson’s disease....Pages 65-73
Motor performance test....Pages 75-82
Measuring body movements in neurological disease, with special reference to Parkinson’s disease....Pages 83-91
Long-term measurement of tremor: early diagnostic possibilities....Pages 93-102
Tremor and electrically elicited long-latency reflexes in early stages of Parkinson’s disease....Pages 103-110
Evoked potentials in Parkinson’s disease....Pages 111-115
Brain mapping of EEG and evoked Potentials during physiological aging and in Parkinson’s disease, dementia and depression....Pages 117-124
Positron emission tomography in Parkinson’s disease glucose metabolism....Pages 125-128
Parkinson’s disease studied using PET....Pages 129-137
Pathobiochemistry of the extrapyramidal system: a “short note” review....Pages 139-149
Dopaminergic neurotransmission and status of brain iron....Pages 151-160
Dopaminergic modulation of neuropeptide gene expression in the rat striatum....Pages 161-169
The diagnostic relevance of Lewy bodies and other inclusions in Parkinson’s disease....Pages 171-180
Cytoskeletal pathology of the Lewy bodies....Pages 181-189
Plasma concentrations of endogenous DOPA and 3-O-methyl-DOPA in rats administered benserazide and carbidopa alone or in combination with the reversible COMT inhibitor Ro 41-0960....Pages 191-196
Catecholamines in urine, blood and cerebrospinal fluid....Pages 197-203
 3 H-spiperone binding to lymphocytes is increased in schizophrenic patients and decreased in parkinson patients....Pages 205-212
Platelet MAO-B activity in humans and stumptail monkeys: in vivo effects of the reversible MAO-B inhibitor Ro 19-6327....Pages 213-219
Aspartate, glutamate, and glutamine in platelets of patients with Parkinson’s disease....Pages 221-227
Hypothalamic dysfunction and neuroendocrine research in Parkinson’s disease....Pages 229-236
The MPTP model: an update....Pages 237-242
Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease?....Pages 243-248
Importance of dopaminergic and GABAergic neurones of the nucleus accumbens and the caudate nucleus for motoricity....Pages 249-256
Is D-1 receptor stimulation important for the anti-parkinson activity of dopamine agonists?....Pages 257-268
Pharmacological and clinical-pharmacological aspects of D 1 and D 2 receptors....Pages 269-277
Chemical modulation of membrane-bound receptors....Pages 279-282
Transplantation of dopamine-synthesizing cells—new therapy for Parkinson’s disease?....Pages 283-304
L-dopa in Parkinson’s disease....Pages 305-311
Pharmacokinetic investigations of various levodopa formulations....Pages 313-322
Iron therapy in Parkinson’s disease....Pages 323-327
Provisional experiences with the combination of L-dopa and L-deprenyl....Pages 329-334
Clinical pharmacology of amantadine and derivatives....Pages 335-341
Dopamine agonist treatment in early Parkinson’s disease....Pages 343-348
Subcutaneous apomorphine in Parkinson’s disease....Pages 349-355
Continuous dopaminergic stimulation with parenteral lisuride in complicated Parkinson’s disease....Pages 357-371
Discussion....Pages 373-432
Back Matter....Pages 433-447